A Single Dose Study of LY2605541 in Participants With Liver Impairment
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to help answer the following research questions:
- To evaluate how much of the study drug (LY2605541) is in the blood of participants with
varying degrees of liver impairment compared to those with normal liver function
- To assess the safety of LY2605541 and any side effects that might be associated with it